JRC Publications Repository

JRC Publications Repository >

Browsing by Author APOSTOLIDIS Christos

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 55 to 74 of 147
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2000High-Linear Energy Transfer (LET) alpha vs Low-LET beta Emitters in Radioimmunotherapy of Solid Tumors: Therapeutic Efficacy and Dose-Limiting Toxicity of 213Bi- vs 90Y-Labeled CO17-1A Fab' Fragments in a Human Colonic Cancer Model.BEHR T.m.; BEHE M.; STABIN M.g.; WEHRMANN E.; APOSTOLIDIS Christos; MOLINET Roger; STRUTZ F.; FAYYAZI A.; WIELAND E.; GRATZ S.t., et alArticles in Journals
2012High-resolution alpha-particle spectrometry of the 230U decay seriesMAROULI MARIA; POMME Stefaan; PAEPEN Jan; VAN AMMEL Raf; JOBBAGY VIKTOR; DIRICAN ABDULLAH; SULIMAN GABRIEL; STROH HEIKO; APOSTOLIDIS Christos; ABBAS Kamel, et alContributions to Conferences
2001Highly Specific Tumor Binding of a 213Bi Labeled Monoclonal Antibody against Mutant E-Cadherin Suggests its Usefulness for Locoregional alpha-Radioimmunotherapy of Diffuse-Type Gastric Cancer.SENEKOWITSCH-SCHMIDTKE R.; SCHUHMACHER C.; BECKER K.; NIKULA T.k.; SEIDL C.; BECKER I.; MIEDERER M.; APOSTOLIDIS Christos; ADAM C.; HUBER Roswitha, et alArticles in Journals
1997Homoscorpionates (Hydridotris(1-pyrazoly)borato Complexes) of the Trivalent 4f Ions. The Crystal and Molecular Structure of ((HB(N2C3H3)3)3LnIII, (Ln=Pr,Nd).APOSTOLIDIS Christos; REBIZANT Jean; VON AMMON R.; DORNBERGER Ernst; MUELLER J.; POWIETZKA B.; NUBER B.Articles in Journals
2004Importance of Receptor Density in Alpha Radioimmunotherapy in B Cell Malignancies: an In-vitro Study.VANDENBULCKE Katja; THIERENS H.; OFFNER Fritz; JANSSENS A.; DE GELDER V.; BACHER K.; PHILIPPE Jan; DE VOS F.; DIERCKX R.; APOSTOLIDIS Christos, et alArticles in Journals
2007An Improved Method for the Production of Ac-225/Bi-213 from Th-229 for Targeted Alpha TherapyZIELINSKA Barbara; APOSTOLIDIS CHRISTOS; BRUCHERTSEIFER FRANK; MORGENSTERN ALFREDArticles in Journals
2009In vitro and in vivo comparison of 226Th and 213Bi-labelled radioconjugates for target alpha therapyBRUCHERTSEIFER Frank; MORGENSTERN Alfred; FRIESEN CLAUDIA; ROSCHER MAREIKE; MILTNER E.; PFOST B.; SENEKOWITSCH-SCHMIDTKE R.; ABBAS Kamel; APOSTOLIDIS ChristosContributions to Conferences
2003In Vitro Evaluation of 231Bi-Rituximab versus External Gamma Irradiation for the Treatment of B-CLL Patients: Relative Biological Efficacy with Respect to Apoptosis Induction and Chromosomal Damage.VANDENBULCKE K.; DE VOS F.; OFFNER Fritz; PHILIPPE Jan; APOSTOLIDIS Christos; MOLINET Roger; NIKULA T.k.; BACHER K.; DE GELDER V.; VRAL A., et alArticles in Journals
2005In Vitro Evaluation of High-LET 213Bi-Therapy Combined to Other Therapeutic Agents for the Treatment of B-CLL.VANDENBULCKE Katja; THIERENS H.; DE VOS F.; PHILIPPE Jan; OFFNER Fritz; APOSTOLIDIS Christos; MORGENSTERN A.; BACHER K.; DE GELDER V.; DIERCKX R., et alArticles in Journals
2006In Vitro Screening for Synergism of High-linear Energy Transfer 213Bi-radiotherapy with other Therapeutic Agents for the Treatment of B-cell Chronic Lymphocytic LeukemiaVANDENBULCKE K.; THIERENS H.; VOS F.d.; OFFNER F.; JANSSENS F.; PHILIPPE J.; APOSTOLIDIS CHRISTOS; MORGENSTERN ALFRED; BACHER K.; DE GELDER V., et alArticles in Journals
2009Inhibition ofMicrometastatic Prostate Cancer Cell Spread in Animal Models By 213BilabeledMultipleTargeted Alpha-RadioimmunoconjugatesLI Y.; SONG E.; ABBAS RIZVI S. M.; POWER C. A.; BERETOV J.; RAJA C.; COZZI P. J.; MORGENSTERN Alfred; APOSTOLIDIS Christos; ALLEN B. J., et alArticles in Journals
2012Interaction of advanced oxide fuels with sodium for Generation IV Sodium cooled Fast ReactorsSMITH ANNA; RAISON Philippe; KONINGS Rudy; CHEETHAM Anthony; COLLE Jean-Yves; BENES ONDREJ; ELOIRDI Rachel; APOSTOLIDIS ChristosContributions to Conferences
2013Interaction of advanced oxide fuels with sodium in operating conditions for Sodium-cooled Fast ReactorsSMITH ANNA; BYKOV DENIS; RAISON Philippe; KONINGS Rudy; COLLE Jean-Yves; WALLEZ G; BENES ONDREJ; APOSTOLIDIS Christos; KOVACS ATTILA; SUARD E., et alContributions to Conferences
2006Interaction of Radiolabeled Antibodies with Fungal Cells and Components of Immune System In Vitro and During Radioimmunotherapy of Experimental Fungal InfectionDADACHOVA E.; BRYAN R.a.; APOSTOLIDIS CHRISTOS; MORGENSTERN ALFRED; ZHANG T.; MOADEL T.; CASADEVALL A.Articles in Journals
2007Interim Analysis of Toxicity and Response in Phase 1 Trial of Systemic Targeted Alpha Therapy for Metastatic MelanomaRAJA C.; GRAHAM P.; ABBAS RIZVI S. M.; SONG E.; GOLDSMITH H.; THOMPSON J.; BOSSERHOFF A.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; KEARSLEY J., et alArticles in Journals
2005Intralesional Targeted Alpha Therapy for Metastatic MelanomaALLEN Barry J.; RAJA C.; RIZVI S.m.a.; LI Y.; TSUI W.; GRAHAM P.; THOMPSON J.; REISFELD R.a.; KEARSLEY J.; MORGENSTERN ALFRED, et alArticles in Journals
2010Investigation of Para-sulfonatocalix[n]arenes [n = 6, 8] as Potential Chelates for 230UMONTAVON Gilles; REPINC Urska; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; ABBAS Kamel; MORGENSTERN AlfredArticles in Journals
2010Investigation of para-sulfonatocalix[n]arenes [n = 6, 8] as potential chelates for 230U†MONTAVON Gilles; REPINC Urska; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; ABBAS Kamel; MORGENSTERN AlfredArticles in Journals
2006Local Trageting of Malignant Gliomas by the Difussible Peptidic Vector DOTAGA-substance PKNEIFEL S.; CORDIER D.; GOOD S.; IONESCU M.; GHAFFARI A.; HOFER S.; KRETSCHMAR M.; TOLNAY M.; APOSTOLIDIS CHRISTOS; WASER B, et alArticles in Journals
2001Lysine Protection against Bismuth Accumulation in the Kidneys when Using 213-Bi-DTPA-MAB.NIKULA T.; APOSTOLIDIS Christos; MOLINET Roger; CARLOS-MARQUEZ R.; BRANDES K.; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
Showing results 55 to 74 of 147

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top